02.01.18
BRAZIL: Royal DSM and Amyris, Inc. have closed the transaction for the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products. The accord was first announced in November 2017.
The consideration for Amyris Brasil Ltda and intellectual property related to farnesene was $58 million plus an additional value share arrangement over a three-year period amounting to $37.5 million, according to DSM.
DSM is continuing existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with specialty compounds until Amyris completes construction of a second facility dedicated to specialty products manufacturing located in Campinas.
The consideration for Amyris Brasil Ltda and intellectual property related to farnesene was $58 million plus an additional value share arrangement over a three-year period amounting to $37.5 million, according to DSM.
DSM is continuing existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with specialty compounds until Amyris completes construction of a second facility dedicated to specialty products manufacturing located in Campinas.
